Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery
Recently, Dai W et al. published a study on Science,1 in which the two lead compounds 11a and 11b were designed and synthesized based on the features of a key enzyme Mpro of SARSCoV-2 (Fig. 1). In particular, compound 11a is a potential drug candidate for coronavirus disease 2019 (COVID-19) with str...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14043
- Acceso en línea:
- https://doi.org/10.1038/s41392-020-00291-8
http://hdl.handle.net/20.500.12010/14043
- Palabra clave:
- Targeting Mpro
Anti SARS-CoV-2
Drug discovery
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)
| id |
UTADEO2_259e2beccddda1d0ab50bb11e7a3274e |
|---|---|
| oai_identifier_str |
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14043 |
| network_acronym_str |
UTADEO2 |
| network_name_str |
Expeditio: repositorio UTadeo |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| title |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| spellingShingle |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery Targeting Mpro Anti SARS-CoV-2 Drug discovery Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| title_short |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| title_full |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| title_fullStr |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| title_full_unstemmed |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| title_sort |
Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery |
| dc.subject.spa.fl_str_mv |
Targeting Mpro Anti SARS-CoV-2 Drug discovery |
| topic |
Targeting Mpro Anti SARS-CoV-2 Drug discovery Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| dc.subject.lemb.spa.fl_str_mv |
Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| description |
Recently, Dai W et al. published a study on Science,1 in which the two lead compounds 11a and 11b were designed and synthesized based on the features of a key enzyme Mpro of SARSCoV-2 (Fig. 1). In particular, compound 11a is a potential drug candidate for coronavirus disease 2019 (COVID-19) with strong anti-SARS-CoV-2 infection activity, good pharmacokinetics characteristics, and low toxicity. Since December 2019, the outbreak of COVID-19 caused by SARS-CoV-22 has caused a serious global public health emergency. So far, the global epidemic is still in the outbreak stage, and the number of new confirmed cases every day has exceeded 100,000 for several days. At present, the main drugs used clinically include interferon-alpha, lopinavir/ritonavir, ribavirin, arbidol, etc. However, these drugs are facing huge controversy due to the large side effects or the lack of clinical verifications of the therapeutic effects.3 Therefore, clarifying the origin and pathogenesis of pneumonia and decoding the key targets against SARS-CoV-2 are the cornerstone to design and discover safe and effective antivirus drugs. |
| publishDate |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2020-09-30T20:43:14Z |
| dc.date.available.none.fl_str_mv |
2020-09-30T20:43:14Z |
| dc.date.created.none.fl_str_mv |
2020 |
| dc.type.local.spa.fl_str_mv |
Artículo |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.identifier.issn.spa.fl_str_mv |
2059-3635 |
| dc.identifier.other.spa.fl_str_mv |
https://doi.org/10.1038/s41392-020-00291-8 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12010/14043 |
| dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1038/s41392-020-00291-8 |
| identifier_str_mv |
2059-3635 |
| url |
https://doi.org/10.1038/s41392-020-00291-8 http://hdl.handle.net/20.500.12010/14043 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.local.spa.fl_str_mv |
Abierto (Texto Completo) |
| rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
| dc.format.extent.spa.fl_str_mv |
2 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Signal Transduction and Targeted Therapy |
| dc.source.spa.fl_str_mv |
reponame:Expeditio Repositorio Institucional UJTL instname:Universidad de Bogotá Jorge Tadeo Lozano |
| instname_str |
Universidad de Bogotá Jorge Tadeo Lozano |
| institution |
Universidad de Bogotá Jorge Tadeo Lozano |
| reponame_str |
Expeditio Repositorio Institucional UJTL |
| collection |
Expeditio Repositorio Institucional UJTL |
| bitstream.url.fl_str_mv |
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14043/2/license.txt https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14043/3/s41392-020-00291-8.pdf.jpg |
| bitstream.checksum.fl_str_mv |
abceeb1c943c50d3343516f9dbfc110f 2746a6779450b0bfce3933b055970868 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Universidad Jorge Tadeo Lozano |
| repository.mail.fl_str_mv |
expeditio@utadeo.edu.co |
| _version_ |
1818152731113684992 |
| spelling |
2020-09-30T20:43:14Z2020-09-30T20:43:14Z20202059-3635https://doi.org/10.1038/s41392-020-00291-8http://hdl.handle.net/20.500.12010/14043https://doi.org/10.1038/s41392-020-00291-8Recently, Dai W et al. published a study on Science,1 in which the two lead compounds 11a and 11b were designed and synthesized based on the features of a key enzyme Mpro of SARSCoV-2 (Fig. 1). In particular, compound 11a is a potential drug candidate for coronavirus disease 2019 (COVID-19) with strong anti-SARS-CoV-2 infection activity, good pharmacokinetics characteristics, and low toxicity. Since December 2019, the outbreak of COVID-19 caused by SARS-CoV-22 has caused a serious global public health emergency. So far, the global epidemic is still in the outbreak stage, and the number of new confirmed cases every day has exceeded 100,000 for several days. At present, the main drugs used clinically include interferon-alpha, lopinavir/ritonavir, ribavirin, arbidol, etc. However, these drugs are facing huge controversy due to the large side effects or the lack of clinical verifications of the therapeutic effects.3 Therefore, clarifying the origin and pathogenesis of pneumonia and decoding the key targets against SARS-CoV-2 are the cornerstone to design and discover safe and effective antivirus drugs.2 páginasapplication/pdfengSignal Transduction and Targeted Therapyreponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoTargeting MproAnti SARS-CoV-2Drug discoverySíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusPromising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discoveryArtículohttp://purl.org/coar/resource_type/c_2df8fbb1Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2Chen, YiWang, GuanOuyang, LiangLICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14043/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILs41392-020-00291-8.pdf.jpgs41392-020-00291-8.pdf.jpgIM Thumbnailimage/jpeg24016https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14043/3/s41392-020-00291-8.pdf.jpg2746a6779450b0bfce3933b055970868MD53open access20.500.12010/14043oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/140432021-03-17 19:49:14.674metadata only accessRepositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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 |